US2006002949A1PendingUtilityA1

Transcutaneous immunization without heterologous adjuvant

Assignee: US GOV SEC ARMYPriority: Nov 14, 1996Filed: Jun 1, 2005Published: Jan 5, 2006
Est. expiryNov 14, 2016(expired)· nominal 20-yr term from priority
C12N 2740/16234A61K 39/099A61K 39/102A61P 31/16A61K 39/107A61K 2039/55522A61K 2039/53A61P 31/10C12N 2760/20134A61K 2039/55555A61K 2039/55561A61P 37/04A61K 39/015A61K 39/104C12N 2760/16234A61K 39/08A61K 2039/54A61K 2039/55533A61K 2039/70A61P 31/04C12N 2760/16134A61K 39/0258A61K 39/05A61K 39/12A61K 2039/545A61P 33/00A61K 2039/55544A61K 2039/5252A61K 39/008A61K 2039/55505A61K 39/116Y02A50/30
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Transcutaneous immunization can deliver antigen to the immune system through the stratum corneum without physical or chemical penetration to the dermis layer of the skin. This delivery system induces an antigen-specific immune response without the use of a heterologous adjuvant. Although perforation of intact skin is not required, superficial penetration or micropenetration of the skin can act as an enhancer; similarly, hydration may enhance the immune response. This system can induce antigen-specific immune effectors after epicutaneous application of a formulation containing one or more antigens. The formulation may initiate processes such as antigen uptake, processing, and presentation; Langerhans cell activation, migration from the skin to other immune organs, and differentiation to mature dendritic cells; contacting antigen with lymphocytes bearing cognate antigen receptors on the cell surface and their stimulation; and combinations thereof. Systemic and/or regional immunity may be induced. Immune responses that provide prophylactic and/or therapeutic treatments are preferred. Antigenic activities in the formulation may be found in the same molecule, two or more different molecules dissociated from each other, or multiple molecules in a complex formed by covalent or non-covalent bonds. For antigens which are proteinaceous, they may be provided in the formulation as a polynucleotide for transcutaneous genetic immunization. Besides simple application of a dry or liquid formulation to the skin, patches and other medical devices may be used to deliver antigen for immunization.

Claims

exact text as granted — not AI-modified
1 - 69 . (canceled)  
     
     
         70 . A method for inducing an antigen-specific immune response in an organism comprising: 
 (a) providing a formulation comprising an antigen;    (b) applying said formulation epicutanesouly to skin of said organism without penetrating said skin's dermis layer, thereby inducing an antigen-specific immune response in said organism.

Join the waitlist — get patent alerts

Track US2006002949A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.